![[ Beasley Allen Law Firm Logo ]](http://www.reglan-lawyer.net/wp-content/themes/system-unity/images/logo.png){kind=logo}
Makers of generic Reglan liable for inadequate warning labels
Makers of generic drugs who do not adequately label their products to warn consumers of possible risks are not exempt from liability, according to a ruling by the U.S. Court of Appeals for the Eighth Circuit. The court ruled on a product liability lawsuit brought by Gladys Mensing, who was prescribed metoclopramide to treat diabetic gastroparesis, a debilitating condition in which the stomach empties too slowly. Following use of the medication, Mensing developed a serious movement disorder known as Tardive Dyskinesia. Research has shown that the condition can be caused by long-term use of metoclopramide. Mensing sued several makers of generic metoclopramide, known by the brand name Reglan, for not adequately warning consumers of the risk of developing the movement disorder.
Millions of people turn to medication to treat the annoying and painful symptoms of heartburn. But doctors say that people who use medications to treat their symptoms should use them with caution and limit use if at all possible.
Last month, a 12-year-old girl’s mysterious sneezing illness promoted a flurry of attention after her story was told on 
Swiss biotech group Addex Pharmaceuticals announced that its lead drug candidate met expectations in a mid-stage clinical trial in heartburn, setting the company up for a lucrative partnership with a bigger drug maker that would provide much-needed funds for the startup company.
The Food and Drug Administration (FDA) has approved a generic version of a drug for treating gastroesophageal reflux disease, or GERD, in adolescents and adults. Amneal Pharmaceuticals’ nizatidine oral solution was approved in the 15-mg-per-15-ml strength, and is a generic version of Axid, made by Braintree Laboratories. The medication belongs to a class of drugs known as histamine H2 blockers.
Findings from a new study on the causes of gastroesophageal reflux disease (GERD) may lead to new way of treating the condition. According to a team of researchers from the University of Texas Southwestern Medical Center, GERD, which causes painful chest pain and heartburn, may be caused by immune system cells causing inflammation. The study showed that gastroesophageal reflux in rats causes tissue in the esophagus to release immune chemicals called cytokines. Those cytokines attract inflammatory cells that cause the uncomfortable symptoms associated with heartburn and GERD.
Most people who take the medication 
Patients who suffer from gastroesophageal reflux disease (GERD) often have to give up their favorite foods because of bothersome symptoms, which can include chronic heartburn, acid reflux, difficulty swallowing and constant belching. Medications can help but they sometimes come with irritating side effects. But a new procedure is offering hope for patients who suffer from GERD.
Thirty-two-year-old Shimmi Munshi would get sick up to 50 times a day over a four-year period, but doctors were at a loss as to why. She was put on feeding tubes and medication, but the treatments did little to help her. She became sicker and weaker. It wasn’t until the young woman scoured the Internet that she some answers. She immediately diagnosed herself with gastroparesis, or paralysis of the stomach. And found a treatment that would help her live a normal life. 